ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $134.2 million versus the consensus estimate of $131.19 million.

GUIDANCE:

ADMA Biologics sees FY2025 revenue of $510 million, versus the consensus of $506.3 million.

ADMA Biologics sees FY2026 revenue of $630 million, versus the consensus of $637.9 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.